Cutting-edge cancer treatments from Switzerland’s Novartis AG and Seattle’s own Juno Therapeutics show great promise in clinical trials, but might face roadblocks when it comes to the costs of getting those drugs to patients, the Wall Street Journal recently reported.
Both of the companies sponsored clinical trials in which experimental chimeric antigen receptor (CAR) T-cell therapies were used on patients, 90 percent of whom saw their leukemia disappear, according to the Journal.
CAR T-cell therapies are a type of immunotherapy that engineers patients’ immune cells to battle their own cancer and is used as an alternative to chemotherapy and radiation therapy.
Help employers find you! Check out all the jobs and post your resume.
